Dan Puckett - 20 Dec 2021 Form 4 Insider Report for Shockwave Medical, Inc.

Signature
/s/ Wade Estey, as attorney-in-fact for Dan Puckett
Issuer symbol
N/A
Transactions as of
20 Dec 2021
Net transactions value
-$430,059
Form type
4
Filing time
21 Dec 2021, 16:12:14 UTC
Previous filing
02 Nov 2021
Next filing
21 Jan 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWAV Common Stock Options Exercise $25,500 +1,500 +3.3% $17.00* 47,288 20 Dec 2021 Direct F1
transaction SWAV Common Stock Sale $80,904 -486 -1% $166.47 46,802 20 Dec 2021 Direct F2
transaction SWAV Common Stock Sale $67,899 -406 -0.87% $167.24 46,396 20 Dec 2021 Direct F3
transaction SWAV Common Stock Sale $93,073 -552 -1.2% $168.61 45,844 20 Dec 2021 Direct F4
transaction SWAV Common Stock Sale $127,095 -750 -1.6% $169.46 45,094 20 Dec 2021 Direct F5
transaction SWAV Common Stock Sale $60,737 -356 -0.79% $170.61 44,738 20 Dec 2021 Direct F6
transaction SWAV Common Stock Sale $8,567 -50 -0.11% $171.34 44,688 20 Dec 2021 Direct F7
transaction SWAV Common Stock Sale $17,283 -100 -0.22% $172.83 44,588 20 Dec 2021 Direct F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWAV Stock Option Options Exercise $0 -1,500 -7.4% $0.000000 18,747 20 Dec 2021 Common Stock 1,500 $17.00 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 8/8/2019.
F2 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $165.93 to $166.75. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $167.02 to $167.42. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $168.02 to $169.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F5 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $169.16 to $170.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F6 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $170.25 to $171.06. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F7 The reported securities were sold at a price of $171.34.
F8 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $172.59 to $173.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F9 1/48th of the shares subject to the option shall vest monthly from 3/6/2019.